NCT06964685View on ClinicalTrials.gov

Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

RecruitingOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

October 30, 2028

Conditions
AMI Cardiogenic Shock
Interventions
DEVICE

Impella

US commercially approved Impella CP is the device that study inclusion will be based on. Only patients with AMICS who receive Impella CP as the first Impella device after cardiogenic shock onset will be included in the study.

Trial Locations (3)

67226

NOT_YET_RECRUITING

Ascension via Christi, Wichita

87102

RECRUITING

New Mexico Heart, Albuquerque

92868

RECRUITING

St. Joseph Hospital Orange, Orange

Sponsors

Lead Sponsor

Abiomed Inc.
All Listed Sponsors
lead

Abiomed Inc.

INDUSTRY